High levels of CD123+ LSCs are negatively correlated with chemotherapy outcomes and prognosis in AML patients, with high CD123 expression at diagnosis serving as an independent prognostic indicator.189. The gene discussed is IL3RA; the disease is acute myeloid leukemia.